253 related articles for article (PubMed ID: 14704897)
1. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effects of olopatadine and ketotifen on model membranes.
Brockman H; Graff G; Spellman J; Yanni J
Acta Ophthalmol Scand Suppl; 2000; (230):10-5. PubMed ID: 11057342
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
4. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
5. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
7. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
[TBL] [Abstract][Full Text] [Related]
8. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
Lee JS; Lee JE; Kim N; Oum BS
J Ocul Pharmacol Ther; 2008 Dec; 24(6):557-62. PubMed ID: 19049267
[TBL] [Abstract][Full Text] [Related]
10. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
[TBL] [Abstract][Full Text] [Related]
11. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
12. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
[TBL] [Abstract][Full Text] [Related]
13. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
14. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.
Lytinas M; Kempuraj D; Huang M; Boucher W; Esposito P; Theoharides TC
Int Arch Allergy Immunol; 2003 Mar; 130(3):224-31. PubMed ID: 12660427
[TBL] [Abstract][Full Text] [Related]
15. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
16. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
18. Olopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformation.
Baba A; Tachi M; Maruyama Y; Kazama I
Cell Physiol Biochem; 2015; 35(1):386-96. PubMed ID: 25591779
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
Yanni JM; Weimer LK; Sharif NA; Xu SX; Gamache DA; Spellman JM
Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
[TBL] [Abstract][Full Text] [Related]
20. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]